Endocrine therapy after aromatase inhibitor therapy in breast cancer

References

• Chen S, Masri S, Hong YY et al. New experimental models for aromatase inhibitor resistance. J. Steroid Biochem. Mol. Biol.106, 8–15 (2007).
   PubMedGoogle Scholar
• Pasqualini JR, Chetrite GS. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J. Steroid Biochem. Mol. Biol.93, 221–236 (2005).
   PubMed Web of Science ®Google Scholar
• Labrie F, Luu-The V, Labrie C et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev.24, 152–182 (2003).
   PubMed Web of Science ®Google Scholar
• Sasano H, Miki Y, Nagasaki S, Suzuki T. In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology. Pathol. Int.59, 777–789 (2009).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Miki Y, Nakamura Y et al. Sex steroid-producing enzymes in human breast cancer. Endocr. Relat. Cancer12, 701–702 (2005).
   PubMed Web of Science ®Google Scholar
• Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis – some new perspectives. Endocrinology142, 4589–4594 (2001).
   PubMed Web of Science ®Google Scholar
• Orlando L, Schiavone P, Fedele P et al. Molecularly targeted endocrine therapies for breast cancer. Cancer Treat. Rev.36(Suppl. 3), S67–S71 (2010).
   PubMed Web of Science ®Google Scholar
• Nagasaki S, Miki Y, Akahira J, Suzuki T, Sasano H. 17β-hydroxysteroid dehydrogenases in human breast cancer. Ann. NY Acad. Sci.1155, 25–32 (2009).
   PubMed Web of Science ®Google Scholar
• Dao TL, Hayes C, Libby PR. Steroid sulfatase activities in human breast tumors. Proc. Soc. Exp. Biol. Med.146, 381–384 (1974).
   PubMed Web of Science ®Google Scholar
• Buzdar AU. Advances in endocrine treatment for postmenopausal women with metastatic and early breast cancer. Oncologist8, 335–341 (2003).
   PubMed Web of Science ®Google Scholar
• The Breast Intergroup 1–98 Collaborative Group; Thürlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med.3533, 2747–2757 (2005).
   Google Scholar
• Miller WR. Markers of sensitivity, dependence and resistance to endocrine therapy for breast cancer. Expert Rev. Endocrinol. Metab.6(3), 345–357 (2011).
   PubMedGoogle Scholar
• Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res.65, 5380–5389 (2005).
   PubMedGoogle Scholar
• Pasqualini JR, Chetrite G, Blacker C et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab.81, 1460–1464 (1996).
   PubMed Web of Science ®Google Scholar
• Chanplakorn N, Chanplakorn P, Suzuki T et al. Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res. Treat.120, 639–648 (2010).
   PubMed Web of Science ®Google Scholar
• Santner SJ, Santen RJ. Inhibition of estrone sulfatase and 17β -hydroxysteroid dehydrogenase by antiestrogens. J. Steroid Biochem. Molec. Biol.45, 383–390 (1993).
   PubMedGoogle Scholar
• Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res.17, 135–140 (1997).
   PubMed Web of Science ®Google Scholar
• Raobaikady B, Day JM, Purohit A, Potter BV, Reed MJ. The nature of inhibition of steroid sulphatase activity by tibolone and its metabolites. J. Steroid Biochem. Mol. Biol.94, 229–237 (2005).
   PubMed Web of Science ®Google Scholar
• Elger W, Schwarz S, Hedden A, Reddersen G, Schneider B. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol.55, 395–403 (1995).
   PubMed Web of Science ®Google Scholar
• Woo LWL, Purohit A, Malini A, Reed MJ, Potter BVL. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem. Biol.7, 773–791 (2000).
   PubMed Web of Science ®Google Scholar
• Stanway SJ, Purohit A, Woo LW et al. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res.12, 1585–1592 (2006).
   PubMed Web of Science ®Google Scholar
• Qiu W, Campbell RL, Gangloff A et al. A concerted, rational design of 17β -hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrid with high affinity. FASEB J.16, 1829–1931 (2002).
   PubMed Web of Science ®Google Scholar
• Husen B, Huhtinen K, Poutanen M, Kangas L, Messinger J, Thole H. Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. Mol. Cell Endocrinol.248, 109–113 (2006).
   PubMedGoogle Scholar
• Oster A, Hinsberger S, Werth R, Marchais-Oberwinkler S, Frotscher M, Hartmann RW. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases. J. Med. Chem.53, 8176–8186 (2010).
   PubMedGoogle Scholar
• Marchais-Oberwinkler S, Wetzel M, Ziegler E et al. New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases. J. Med. Chem.54, 534–547 (2011).
   PubMedGoogle Scholar
• Starčević S, Kocbek P, Hribar G, Lanišnik Rižner T, Gobec S. Biochemical and biological evaluation of novel potent coumarin inhibitor of 17β-HSD type 1. Chem. Biol. Interact. DOI:10.1016/j.cbi.2011.01.002 (2011) (Epub ahead of print).
   PubMedGoogle Scholar